Nanodelivery systems for improved topical antimicrobial therapy

Current Pharmaceutical Design

Volumn 19, Issue 41, 2013, Pages 7237-7243

  Basnet, Purusotam ^a,b   Škalko Basnet, Nataša ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Antimicrobials; Drug delivery; Nanomedicine; Nanotechnology; Skin and wound

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ETHOSOME; HIGHLY DEFORMABLE ELASTIC LIPOSOME; HIGHLY DEFORMABLE ULTRAFLEXIBLE LIPOSOME; LIPOSOME; NANOCAPSULE; NANOCARRIER; NANOFIBER; NITRIC OXIDE; POLYPEPTIDE ANTIBIOTIC AGENT; SILVER NANOPARTICLE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; VANCOMYCIN; NANOPARTICLE;

ACTINOBACTERIA; ANTIMICROBIAL THERAPY; BACTEROIDETES; BIOFILM; DRUG DELIVERY SYSTEM; EPIDERMIS STRATUM GERMINATIVUM; FIRMICUTES; HAIR FOLLICLE; NANOMEDICINE; NANOTECHNOLOGY; PARTICLE SIZE; PRIORITY JOURNAL; PROTEOBACTERIA; REVIEW; SKIN EPITHELIUM; SKIN FLORA; SKIN INFECTION; SKIN PENETRATION; STRATUM CORNEUM; TOPICAL TREATMENT; WOUND DRESSING; ANIMAL; HUMAN; METABOLISM; PROCEDURES; SKIN DISEASES, INFECTIOUS; TOPICAL DRUG ADMINISTRATION; TRENDS;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFECTIVE AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; SKIN DISEASES, INFECTIOUS;

EID: 84890945047     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161281941131219124856     Document Type: Review

References (65)

1. The World Health Organization, The global burden of disease. 2004 update. 2008
2. Murray JL, Lopez D. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997; 349: 1498-504.
3. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine-Challenge and perspectives. Angewandte Chemie 2009; 48: 872-97.
4. Kong HH, Segre J.A. Skin microbiome: Looking back to move forward. J Invest Dermatol 2012; 132: 933-9.
5. Yang D, Pornpattananangkul D, Nakatsuji T, et al. The antimicrobial activity of liposomal lauric acids against Propionibacterium acnes. Biomaterials 2009; 30: 6035-40.
6. Martin JM, Zenilman, JM, Lazarus GS. Molecular microbiology: New dimensions for cutaneous biology and wound healing. J Invest Dermatol 2010; 130: 38-48.
7. Lynch AS, Abbanat D. New antibiotic agents and approaches to treat biofilm-associated infections. Expert OpinTher Patents 2010; 20: 1373-87.
8. Shukla A, Fleming KE, Chung HF, et al. Controlling the release of peptide antimicrobial agents from surfaces. Biomaterials 2010; 31: 2348-57.
9. Martinez LR, Han G, Chacko M, et al. Antimicrobial and healing efficacy of sustained release nitric oxide nanoparticles against Staphylococcus aureus skin infections. J Invest Dermatol 2009; 129: 2463-9.
10. Sanderson NM, Jones MN. Encapsulation of vancomycin and gen-tamicin within cationic liposomes for inhibition of growth of Staphylococcus epidermidis. J Drug Targeting 1996; 4: 181-9.
11. Yang W, Wiederhold P, Williams III RO. Drug delivery strategies for improved azole antifungal action. Expert Opin Drug Deliv 2008; 5: 1199-216.
12. Zhang L, Pornpattananangkul D, Hu CMJ, Huang CM. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem 2010; 17: 585-94.
13. Yacoby I, Benhar I. Antibacterial nanomedicine. Nanomedicine 2008; 3: 329-41.
14. Zafeiris S. Antibiotics, A shot in the arm. Nature 2004; 431: 892-3.
15. Greenhalgh K, Turos E. In vivo studies of polyacrylate nanoparticle emulsions for topical and systemic applications. Nanomedicine 2009; 5: 46-54.
16. Abeylath SC, Turos E. Drug delivery approaches to overcome bacterial resistance to p-lactam antibiotics. Expert Opin Drug Deliv 2008; 5: 931-49.
17. Hetrick EM, Shin JH, Paul HS, Schoenfisch MH. Anti-biofilm efficacy of nitric oxide-relasing silica nanoparticles. Biomaterials 2009; 30: 2782-9.
18. Rizzi SC, Upton N, Bott K, Dargaville TR. Recent advances in dermal wound healing: biomedical device approaches. Experts Reviews 2010; 7: 143-54.
19. Hurler J, Skalko-Basnet N. Advancements in burn therapy: Promise of nanomedicine, in Burns: Prevention, Causes and Treatment, (Eds. E.S. McLaughlin and A.O. Paterson) Nova Science Publishers, New York, pp. 39-63.
20. Blecher K, Nasir A, Friedman A. The growing role of nanotech-nology in combating infectious disease. Virulence 2011; 2: 395-401.
21. Singh AV, AS A, Gade WN, Vats T, Lenardi C, Milani P. Nano-materials: New generation therapeutics in wound healing and tissue repair. Curr Nanosci 2010; 6: 577-86.
22. Prow TW, Grice JE, Lin LL, et al. Nanoparticles and microparti-cles for skin drug delivery. Adv Drug Deliv Rev 2011; 63: 470-91.
23. Huh AJ, Kwon YJ. "Nanoantibiotics": A new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Controlled Rel 2011; 156: 128-45.
24. Papakostas D, Rancan F, Sterry W, Blume-Peytavi U, Vogt A. Nanoparticles in dermatology. Arch Dermatol Res 2011; 303: 533-50.
25. Kristl J, Teskac K, AhlinGrabnar P. Current view on nanosized solid lipid carriers for drug delivery to skin. J Biomed Nanotechnol 2010; 6: 529-42.
26. Couvreur P, Vauthier C. Nanotechnology: Intelligent design to treat complex disease. Pharm Res 2006; 23: 1417-50.
27. Cortivo R, Vindigni V, Iacobellis L, Abatangelo G, Pinton P, Zavan B. Nanoscale particle therapies for wounds and ulcers. Nanomedicine 2010; 5: 641-56.
28. DeLoiuse LA. Applications of nanotechnology in dermatology. J Invest Dermatol 2012; 132: 964-75.
29. Chakraborty SP, Sahu SK, Mahapatra SK, et al. Nanoconjugated-vancomycin: new opportunities for the development of anti-VRSA agents. Nanotechnology 2010; 21: 1-9.
30. Samberg ME, Oldenburg SJ, Monteiro-Riviere NA. Evaluation of sliver nanoparticle toxicity in skin in vivo and keratinocyte in vitro. EHP 2010; 118: 407-13.
31. TM dressings in burns: What is the evidence? Burns 2010; 36: 751-8.
32. Chaloupka K, Malam Y, Seifalian AM. Nanosilver as a new generation of nanoproduct in biomedical applications. Trends Biotech. 2010; 28: 580-8.
33. Carlson C, Hussain SM, Schrand AM, et al. Unique cellular interaction of silver nanoparticles: Size dependent generation of reactive oxygen species. J Phys Chem 2008; 112: 13608-19.
34. Christensen FM, Johnston HJ, Stone V, et al. Nano-silver - feasibility and challenges for human health risk assessment based on open literature. Nanotoxicology 2010; 4: 284-95.
35. Jones ML, Ganopolsky JG, Labbé A, Wahl C, Prakash S. Antimicrobial properties of nitric oxide and its application in antimicrobial formulations and medical devices. Appl Microbiol Biotechnol 2010; 88: 401-7.
36. Friedman AJ, Han G, Navati MS, et al. Sustained release nitric oxide releasing nanoparticles: Characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide 2008; 19: 17-20.
37. Mezei M, Gulasekharam V. Liposomes-a selective drug delivery system for the topical route of administration. Lotion dosage form. Life Sci 1980; 26: 1473-7.
38. Elsayed MMA, Abdallah OY, Nagger VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: Reviewing three decades of research. Int J Pharm 2007; 332: 1-16.
39. Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Res 2004; 56: 675-711.
40. Honeywell-Nguyen PL, Bouwstra JA. Vesicles as tool for transdermal and dermal delivery. Drug Discov Today Techol 2005; 2: 67-74.
41. Korting HC, Schäfer-Korting M. Carriers in the topical treatment of skin disease in Drug Delivery (ed. M Schäfer-Korting), Handbook of Experimental Pharmacology. Springer-Verlag Berlin 2010; 197: 435-67.
42. Skalko N, Cajkovac M, Jalsenjak I. Liposomes with clindamycin hydrochloride in the therapy of Acne vulgaris. Int J Pharm 1992; 85: 97-101.
43. Kim H-J, Jones MN. The delivery of benzyl penicillin to Staphylococcus aureus biofilms by use of liposomes. J Liposome Res 2004; 14: 123-39.
44. Skalko N, Cajkovac M, Jalsenjak I. Liposomes with metronidazole for topical use: the choice of preparation method and vehicle, J Liposome Res 1998; 8: 283-93.
45. Vanic Z, Bego M., Hafner A, Skalko-Basnet N. The characterization of various deformable liposomes with metronidazole. Drug DevInd Pharm 2013; 39(3): 481-8.
46. Vogt PM, Reimer K, Hauser J, et al. PVP-iodine in hydrosomes and hydrogel - A novel concept in wound therapy leads to enhanced epithelialisation and reduced loss of skin grafts. Burns 2006; 32: 698-705.
47. Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta 1992; 1104: 226-32.
48. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes-novel carriers for enhanced delivery: characterization and skin penetration properties. J Control Release 2000; 65: 403-18.
49. Touitou E, Godin B, Weiss C. Enhanced delivery of drugs into and across the skin by ethosomal carriers. Drug Dev Res 2000; 50: 406-15.
50. Horwitz E, Pisanty S, Czerninski R, Helser M, Eliav E, Touitou E. A clinical evaluation of a novel liposomal carrier for acyclovir in the topical treatment of recurrent herpes labialis. Oral Surg Oral Med Oral Pathol Oral Radio Endod 1999; 87: 700-5.
51. Godin B, Touitou E. Erythromycin ethosomal systems: physico-chemiocal characterization and enhanced antibacterial activity. Curr Drug Deliv 2005; 2: 269-75.
52. Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004; 278: 71-7.
53. Sanna V, Gavini E, Cossu M, Rassu G, Giunchedi P. Solid lipid nanoparticles (SLN) as carriers for topical delivery of econazole nitrate: in-vitro characterization, ex-vivo and in-vivo studies. J Pharm Pharmacol 2007; 59: 1057-64.
54. Teskac, K, Kristl, J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm 2010; 39: 61-9.
55. Burger C, Hsiao BS, Chu B. 2006 Nanofibrous materials and their applications. Ann Rev Material Res 2006; 36: 333-68.
56. Hromadka M, Collins JB, Reed C, et al. Nanofiber applications for burn care. J Burn Care Res 2008; 29: 695-703.
57. Min BM, Lee SW, Lim JN, et al. Chitin and chitosan nanofibers: electrospinning of chitin and deacetylation of chitin nanofibers. Polymer 2004; 45: 7137-42.
58. Nhung DTT, Freydiere A-M, Constant H, Falson F, Pirot F. Sustained antibacterial effect of a hand rub gel incorporating chlor-hexidine-loaded nanocapsules (Nanochlorex®). Int J Pharm 2007; 334: 166-72.
59. Nasir A. Nanotechnology and dermatology: Part II-risks of nanotechnology. ClinDermatol 2010; 28: 581-8.
60. Bouwstra JA, Ponec M. The skin barrier in healthy and diseased state. Biochim Biophys Acta 2006; 1758: 2080-95.
61. Teskac Plajnsek, K, Pajk, S, Govedarica, B, Pecer S, Srcic S, Kristl J. A novel fluorescent probe for more effective monitoring of nanosized drug delivery systems within the cells. Int J Pharm 2011; 416: 384-93.
62. Basnet P. Modern Medicine and Pharmaceutics (Ed. Purusotam Basnet) Promising Pharmaceuticals published by InTech, Open Access Publisher (ISBN 978-953-51-0631-9), 2012; pp 1-18.
63. Peng CC, Yang MH, Chiu WT, et al. Composite nano-titanium oxide-chitosan artificial skin exhibits strong wound-healing effect -An approach with anti-inflammatory and bactericidal kinetics. Macromol Biosci 2008; 8: 316-27.
64. Mak WC, Richter H, Patzelt A, et al. Drug delivery into the skin by degradable particles. Eur J Pharm Biopharm 2011; 79: 23-7.
65. Mak WC, Patzel A, Richter H, et al. Triggering of drug release of particles in hair follicles. J Control Release 2012; 160: 509-14.